Combination research — study-design reference
GLP-1 / dual-agonist combination research — study-design reference (2026)
Methodological reference for designing GLP-1 / dual-agonist combination research: mono- vs dual-agonist selection, titration logic anchored to published trial schedules, biomarker panels and outcome instrumentation. URL retained for SEO continuity.
Compound selection rationale
The primary methodological choice in any modern GLP-1 / dual-agonist combination research model is whether to use a mono-agonist (semaglutide) as the reference or a dual agonist (tirzepatide) as the comparator-of-record. SURPASS-2 and SURMOUNT-5 (see /trials/surmount-5) reported greater mean body-weight reduction with tirzepatide at comparable doses in the studied populations, but mono-agonist designs retain advantages for studies that need a clean GLP-1 mechanism without GIP-receptor confounding.
Reference research design (2026)
- Primary compound: tirzepatide weekly, titrated using the published SURMOUNT-1 schedule (research-record only; not a prescribing recommendation).
- Comparator: semaglutide 2.4 mg weekly, titrated using the published STEP-1 schedule.
- Baseline period: 4 weeks of stable diet and activity baselining with weekly anthropometry.
- Treatment period: 24-48 weeks aligned to whichever endpoint set is primary (HbA1c, body composition by DXA, hepatic fat by MRI-PDFF).
- Washout: 4-6 half-lives (~4 weeks for either compound).
Biomarker panel
A complete metabolic-research panel for either compound captures: fasting glucose, HbA1c, fasting and post-OGTT insulin and C-peptide, comprehensive lipid panel (LDL-C, HDL-C, triglycerides, ApoB), high-sensitivity CRP, GGT and ALT (for hepatic monitoring), and body composition by DXA at minimum. MRI-PDFF is the standard hepatic-fat endpoint where centre access exists; visceral adipose tissue volume by MRI is the standard for body-composition refinement.
Methodological cautions
GI side-effect intensity correlates strongly with titration rate; protocols that accelerate titration tend to lose participants disproportionately at higher doses, confounding intention-to-treat analyses. Plan titration intervals to match the published trial schedules unless deviation is methodologically required. For interpretation literacy see the how to read metabolic peptide trials primer and the comparing trials without overclaiming primer.
See the tirzepatide, semaglutide and retatrutide profiles for full safety dossiers and methodological references.
- It does not provide a protocol for combined human use of any medicines or research compounds.
- It does not provide dosing schedules, titration protocols, or self-administration guidance.
- It does not establish the suitability of any combination for any individual.
- Methodological framing for authorised research only.